IRDiRC is delighted to present the outcome of the collaboration between the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Rare Disease Moonshot and the IRDiRC Companies Constituent Committee: “The different contributions of the industry in Public-Private Partnerships in Rare Diseases Research continuum” report, which marks a pivotal moment in research advancement, innovation and […]
Read More
The RealiseD project, funded under the Innovative Health Initiative (IHI), emerged in direct response to the strategic priorities set by the Rare Disease Moonshot. The Moonshot’s Clinical Trials Research Needs Recommendations provided a structured foundation that helped shaping RealiseD’s objectives, methodologies, direction and expected outcomes. The origins of RealiseD can indeed be traced back to the EFPIA-EURORDIS Joint Statement on […]
Read More
Connect4Children (c4c), funded by the Innovative Medicines Initiative 2 Joint Undertaking, a public–private partnership between the European Union and the European pharmaceutical industry, has just released a publication on the need for standardized disease-specific data and reviewed multiple initiatives, data resources, and data standards that could be utilised for this purpose. It is widely recognised […]
Read More
The European Joint Programme on Rare Diseases, together with the Companies Constituent Committee (CCC) member EFPIA, is organizing the training webinar: “Real-World data, Machine learning and Deep analytics in rare diseases: Regulatory grade data collection for marketing authorization submissions – what is buzz, what is realistic?” that will be held online on 26 January 2024 […]
Read More